Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

Deutsche Bank upgraded Boston Scientific (BSX) to Buy from Hold with a price target of $108, up from $87. Boston Scientific’s :story has become ...

The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.